Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trial

OBJECTIVES: To determine whether the tumor necrosis factor α inhibitor etanercept is well tolerated and obtain preliminary data on its safety in Alzheimer disease dementia. METHODS: In a double-blind study, patients with mild to moderate Alzheimer disease dementia were randomized (1:1) to subcutaneo...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Neurology
Main Authors: Butchart, Joseph, Brook, Laura, Hopkins, Vivienne, Teeling, Jessica, Püntener, Ursula, Culliford, David, Sharples, Richard, Sharif, Saif, McFarlane, Brady, Raybould, Rachel, Thomas, Rhodri, Passmore, Peter, Perry, V. Hugh, Holmes, Clive
Format: Artigo
Jezik:Inglês
Izdano: Lippincott Williams & Wilkins 2015
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4451045/
https://ncbi.nlm.nih.gov/pubmed/25934853
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/WNL.0000000000001617
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki